Investigating urinary and sexual function after laparoscopic surgery for rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the protective effects of laparoscopic functional total mesorectum excision (FTME) on urinary and sexual function in male patients with mid-low rectal cancer. It is a prospective, single-arm, multicenter, uncontrolled clinical study involving 88 eligible subjects. Participants will undergo laparoscopic FTME surgery, and their demographic information, surgical details, postoperative outcomes, and follow-up data will be collected and analyzed. The study seeks to provide higher-level evidence regarding the benefits of this surgical approach in preserving nerve function.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male, 18-70 years of age, informed consent;
2. Tumors from anal edge 6 \~ 12 cm (measured by rigid proctoscope);
3. Rectal cancer confirmed pathologically by endoscopic biopsy;
4. Preoperative cT1-3aN0M0 stage (ESMO, 2013);
5. Ro resection is expected;
6. Normal urinary function, normal erection function and ejaculation function grading as I level;

Exclusion Criteria:

1. History of abdominal and pelvic major surgery;
2. Emergency surgery is needed due to the complication (bleeding, obstruction, or perforation) caused by rectal cancer;
3. Pelvic or distant metastasis;
4. Neoadjuvant radiotherapy or chemoradiotherapy;
5. No sexual life;

Where it's running

• Yongbin Zheng
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Yongbin Zheng, M.D,Ph.D — Renmin Hospital of Wuhan University
• Study coordinator: Yongbin Zheng, M.D,Ph.D
• Email: yongbinzheng@whu.edu.cn
• Phone: 13871189698

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single vs. double stapling and purse-string techniques after rectal cancer surgery

  This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.

  Recruiting Alexandria University · Alexandria · NCT07929415

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• Rectal cancer registry to track real-world treatments and outcomes

  This registry collects real-world data on how locally advanced rectal cancer is treated in Austria, to see how TNT and dMMR/MSI-H cases are managed and what outcomes occur.

  Recruiting at 2 sites Austrian Breast & Colorectal Cancer Study Group · Wiener Neustadt, Lower Austria and 5 other locations · NCT07780305

• Aerobic exercise and guided imagery for bowel problems after rectal cancer surgery

  This study tests whether a program of aerobic exercise plus guided imagery helps people with low anterior resection syndrome after rectal cancer surgery.

  Recruiting Biruni University · Istanbul · NCT07732894

• Active surveillance vs chemoradiotherapy after local removal of intermediate-risk T1 rectal cancer

  This study tests whether close follow-up alone after local removal of early rectal cancer can match the cancer control of adding chemoradiotherapy, while reducing treatment-related side effects.

  Recruiting at 2 sites Medical University of Gdansk · Limoges and 2 other locations · NCT07669298

• Different-Dose Short-Course Radiotherapy With CAPOX, PD-1 Blockade, and IL-2 in Locally Advanced Rectal Cancer

  This phase II trial tests whether a low-dose short-course radiotherapy combined with CAPOX, a PD-1 blocker, and IL-2 works as well as the standard-dose short-course approach in patients with locally advanced rectal cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07646639

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.